Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.
Study design: * Experiment duration: 22 days * 2 visits (days 0,7,15 and 22) * Reducing eczema area and severity index evaluation * Adverse events evaluation * Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
76
applied 3 times / day at lesion
applied 3 times / day at lesion
Reduction / improvement of signs and symptoms
The reduction of signs and symptoms will be evaluated by OSAAD index.
Time frame: DAY 22
Adverse Events Evaluation
Adverse events will be collected and followed in order to evaluate safety and tolerability.
Time frame: DAY 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.